Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems
- 277 Downloads
Food supplements containing red yeast rice (RYR) are proposed as an alternative in statin-intolerant patients, although they actually contain natural statin(s) and their safety in clinical practice is still incompletely characterized. We described and compared adverse events (AEs) associated with RYR products submitted to reporting systems maintained by the Food and Drug Administration (FDA), with a focus on liver and muscular events.
We extracted RYR-related AEs from the FDA Adverse Event Reporting System (FAERS) [first quarter (Q1)-2004 to Q2-2016], a drug-based archive, and the Center for Food Safety and Applied Nutrition Adverse Event Reporting System (CAERS) (Q1-2004 to Q1-2017). Disproportionality via reporting odds ratio (ROR) with 95% confidence interval (CI) calculation and case-by-case inspection were performed, with a focus on muscular and hepatic AEs.
One thousand three hundred AEs were extracted from FAERS (RYR mainly reported as a concomitant agent), whereas only 159 AEs were found in CAERS (RYR recorded mainly as a suspect agent). In FAERS, a large number of reports emerged for “general disorders and administration site conditions,” whereas CAERS received also a high number of reports for “investigations” and “musculoskeletal and connective tissue disorders”. Disproportionality analyses confirmed higher reporting of serious muscular and liver injuries: in FAERS, five cases of hepatic disorders (ROR = 13.71; 95% CI 5.44–34.57); in CAERS, 27 cases of rhabdomyolysis/myopathy (8.44; 5.44–13.10).
Notwithstanding recognized limitations, these findings strengthen the importance of exploring multiple databases in safety assessment of RYR products, which should be monitored by clinicians for muscular and hepatic safety, and call for urgent review by policymakers to harmonize their regulatory status.
E.R. conceived and designed the study, provided guidance with regard to data analysis, and drafted the first version of the manuscript; A.G. and E.F. analyzed the data and provided substantial contributions to data interpretation and discussion; E.P., F.M.I., G.M. and F.D.P. provided substantial contributions to the study design, data interpretation and discussion; all authors critically revised the content and approved the final version of the manuscript.
Compliance with Ethical Standards
No sources of funding were used to assist in the preparation of this study. Authors at the University of Bologna (E.R., A.G., E.P., E.F., F.D.P.) are supported by Institutional Research Funds (Ricerca Fondamentale Orientata).
Conflicts of Interest
Emanuel Raschi, Anna Girardi, Elisabetta Poluzzi, Emanuele Forcesi, Francesca Menniti-Ippolito, Gabriela Mazzanti and Fabrizio De Ponti declare no potential conflicts of interest relevant to the content of the manuscript.
- 2.Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements. 2002. http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32002L0046&from=EN. Accessed 15 Feb 2018.
- 8.Timbo BB, Chirtel SJ, Ihrie J, Oladipo T, Velez-Suarez L, Brewer V, et al. A review of dietary supplement adverse event report data from the FDA Center for Food Safety and Applied Nutrition Adverse Event Reporting System (CAERS), 2004–2013. Ann Pharmacother. 2017. https://doi.org/10.1177/1060028017744316.PubMedGoogle Scholar
- 10.Agostoni C, Bresson JL, Fairweather-Tait S, Flynn A, Golly I, Korhonen H, et al. Scientific opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL cholesterol concentrations (ID 1648, 1700) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J. 2011;9:2304–20.Google Scholar
- 15.Pirro M, Vetrani C, Bianchi C, Mannarino MR, Bernini F, Rivellese AA. Joint position statement on “Nutraceuticals for the treatment of hypercholesterolemia” of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA). Nutr Metab Cardiovasc Dis. 2017;27:2–17.CrossRefPubMedGoogle Scholar
- 16.Catapano AL, Graham I, De BG, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281–344.CrossRefPubMedGoogle Scholar
- 23.Opinion of the French Agency for Food, Environmental and Occupational Health & Safety (ANSES) on the risks associated with the presence of ‘red yeast rice’ in food supplements. https://www.anses.fr/fr/system/files/NUT2012sa0228EN.pdf. Accessed 15 Feb 2018.
- 24.CFSAN adverse event Reporting System (CAERS)—Data Files. https://www.fda.gov/Food/ComplianceEnforcement/ucm494015.htm. Accessed 15 Feb 2018.
- 25.FDA Adverse Event Reporting System (FAERS): Latest quarterly data files. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082193.htm. Accessed 15 Feb 2018.
- 26.Poluzzi E, Raschi E, Piccinni C, De Ponti F. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA Adverse Event Reporting System (AERS). In: Karahoca A, editor. Data mining applications in engineering and medicine. Croatia: InTech; 2012. p. 265–302.Google Scholar
- 36.Lachenmeier DW, Steffen C, el-Atma O, Maixner S, Lobell-Behrends S, Kohl-Himmelseher M. What is a food and what is a medicinal product in the European Union? Use of the benchmark dose (BMD) methodology to define a threshold for “pharmacological action”. Regul Toxicol Pharmacol. 2012;64:286–95.CrossRefPubMedGoogle Scholar
- 37.BVL/BfArM, Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL) und das Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). 2016. https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Zulassung/ZulRelThemen/abgrenzung/Expertenkommission/stellungnahmen/2016-02.pdf?__blob=publicationFile&v=5. Accessed 15 Feb 2018.